Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Updates in Small Interfering RNA for the Treatment of Dyslipidemias

4 Oct 2023

Abstract excerpt

PURPOSE OF REVIEW: Atherosclerotic cardiovascular disease (ASCVD) is still the leading cause of death worldwide. Despite excellent pharmacological approaches, clinical registries consistently show that many people with dyslipidemia do not achieve optimal management, and many of them are treated with low-intensity lipid-lowering therapies. Beyond the well-known association between low-density lipoprotein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes, Cardiovascular Risks, and Lipoproteins
Share to Lipid metabolism and disorders
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37792132
DOI: 10.1007/s11883-023-01156-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Updates in Small Interfering RNA for the Treatment of DyslipidemiasPMID 37792132Read ↗

Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?Semantic proximity Read ↗

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseSemantic proximity Read ↗

Nucleic Acid–Based Therapies for AtherosclerosisSemantic proximity Read ↗

Inclisiran—Silencing the Cholesterol, Speaking up the PrognosisSemantic proximity Read ↗

Gene-based therapy in lipid management: the winding road from promise to practiceSemantic proximity Read ↗

RNA Silencing in the Management of DyslipidemiasSemantic proximity Read ↗

Advances in nucleic acid-targeted therapies for cardiovascular disease preventionSemantic proximity Read ↗

A new dawn for managing dyslipidemias: The era of rna-based therapiesSemantic proximity Read ↗

Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factorSemantic proximity Read ↗

Treatment of Lp(a): Is It the Future or Are We Ready Today?Semantic proximity Read ↗

ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.Semantic proximity Read ↗

Weekly journal scan: a new small-interfering RNA to fight a genetic cardiovascular risk factor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.